TOP-5 Price Targets of Analysts on October 23, 2025
Reading Time: 3 minutes
Savara Inc. [US8051111016] Citizens JMP confirms Buy rating and raises price target from $8 to $11 (163% upside potential) The background for this positive assessment is an in-house survey among lung specialists, in which 60% of respondents indicated that they intend to use Molbreevi . Savara is continuing on track to resubmit the application for Molbreevi in December of this year. Molbreevi is a drug for the treatment of autoimmune pulmonary alveolar proteinosis ( aPAP ), a rare lung disease. UP Fintech [US91531W1062] UBS initiates...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
